Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.
about
CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) miceAltered Macrophage and Dendritic Cell Response in Mif-/- Mice Reveals a Role of Mif for Inflammatory-Th1 Response in Type 1 DiabetesHuman 4-1BB regulates CD28 co-stimulation to promote Th1 cell responsesSignal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor moleculesType 1 diabetes: translating mechanistic observations into effective clinical outcomesLate engagement of CD86 after influenza virus clearance promotes recovery in a FoxP3+ regulatory T cell dependent manner.Naturally occurring immunoglobulin M (nIgM) autoantibodies prevent autoimmune diabetes and mitigate inflammation after transplantationCD28 and ITK signals regulate autoreactive T cell trafficking.APC activation restores functional CD4(+)CD25(+) regulatory T cells in NOD mice that can prevent diabetes development.Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with idiopathic thrombocytopenic purpura in a Chinese population.Lack of impact of cytotoxic T-lymphocyte antigen 4 gene exon 1 polymorphism on susceptibility to or clinical course of egyptian childhood immune thrombocytopenic purpura.Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.Immunomodulation by interference with co-stimulatory molecules: therapeutic perspectives in asthma.The role of B7 costimulation in T-cell immunity.Modulation of murine Lyme borreliosis by interruption of the B7/CD28 T-cell costimulatory pathway.Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.Long-term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infectionAutoimmune effector memory T cells: the bad and the goodBlocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease.Hormonal regulation of CD4(+) T-cell responses in coxsackievirus B3-induced myocarditis in miceUsefulness of liver infiltrating CD86-positive mononuclear cells for diagnosis of autoimmune hepatitis.Dynamic equilibrium of B7-1 dimers and monomers differentially affects immunological synapse formation and T cell activation in response to TCR/CD28 stimulation.CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activationCD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis.Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathwayCognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses.CD28, CTLA-4 and their ligands: who does what and to whom?CTLA4-Ig: a novel immunosuppressive agent.Use of nonobese diabetic mice to understand human type 1 diabetesGenetically manipulated bacterial toxin as a new generation mucosal adjuvant.CTLA4Ig: a novel inhibitor of costimulation.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma.Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitisAbatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis.Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases.B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function.
P2860
Q22008700-29D6EEE0-4755-487D-9F4D-32D80CA1BBA3Q24670319-D8FAD20A-AC52-4B1D-BE35-8986BA4BD449Q27349718-C1CFB7F2-C013-4D51-B567-B40B030D19E5Q28267489-9DFCE57D-5011-4DEA-96E0-348EB31CFE80Q28274276-08B71014-545A-41E6-BB66-A0A624933DB7Q28287737-23812990-CF69-4A22-A464-123DF270FF98Q30411194-9BDD257C-179E-42E0-B28B-7D902AFF589DQ30415616-92ED85AC-87C8-47C7-A534-AEC829069B52Q30577349-34B93048-CDFD-456A-AE35-4746B657BC20Q33384634-317EC824-45FC-425D-B4B3-2E077DF6D7C9Q33392564-D2BC1E33-F44F-4855-955A-37BFBCD28F01Q33410250-2F44FDEE-7869-4383-BF9B-8E910E8F3259Q33637013-3D8C6877-2392-43E5-B7DD-F1DBA402CA9FQ33639360-0CC9DDE0-4ACC-4873-B082-9D806559B889Q33717482-61A75CC2-3894-4CF9-8FE7-5955C7262C84Q33748591-E15CCB01-4AAB-453D-A829-F8AA76962B18Q33760317-7795D397-23DE-4697-A8E0-93BFB7F1F1BFQ33784950-7A23C92C-8002-4D3C-9BF2-CD040EFB4A7AQ33794691-7F922D82-8FB2-45E4-B314-66E845639ECBQ33805849-DC05C9CE-02E0-4687-98D8-CADFB9374675Q33813631-8BFE3877-7882-424A-8CAB-FC14F00ACDEFQ33868482-4A9BD270-A9EE-4691-A5ED-65E6190B89C0Q33869611-EFA405EC-F523-4600-BB87-1652E94C9FF1Q33873833-B40DF6EC-F3E2-4D9F-A17B-3F6DF713D71CQ33883311-58D7EBDE-667A-4A38-9DD9-622849AEF720Q33939286-A3423D1A-8F28-4198-8078-0D05599145BAQ34001670-A39399CB-EB24-41B3-B36E-F1928797B81CQ34002718-4950F821-BEE6-40AE-93C9-2D2D2C6105DEQ34033524-4B36BA52-9B45-4443-A1C0-EA90EE4A8B5DQ34049974-25D230D1-B1C0-40DF-8426-C7A87B53D9D9Q34075083-227212D8-FE35-4BC0-BECB-17E9CD60A93BQ34078163-F76BA2A2-835E-4503-99FE-A1C01460609CQ34184890-A85D3FDD-A224-405A-8F3B-E20C7207FE21Q34330606-A650ACA8-713C-46D8-98D7-583FAA7E0770Q34375578-50E77BB8-1D88-4044-BA20-DF25A64DB99FQ34437969-264C21CC-81F1-458A-BF9A-075415CF366DQ34535189-C8F417C9-52CF-43B1-A790-7A9B4DE9C7BDQ34560362-DC475FAE-F8D2-4A99-AC15-BD1D0C284726Q34731064-511B0558-1CF5-4AD3-A5FF-0B9E6C1AFB24Q34788681-4D7D7166-3EED-4009-B405-CEC1B1F9523F
P2860
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Differential effects of anti-B ...... n the nonobese diabetic mouse.
@ast
Differential effects of anti-B ...... n the nonobese diabetic mouse.
@en
type
label
Differential effects of anti-B ...... n the nonobese diabetic mouse.
@ast
Differential effects of anti-B ...... n the nonobese diabetic mouse.
@en
prefLabel
Differential effects of anti-B ...... n the nonobese diabetic mouse.
@ast
Differential effects of anti-B ...... n the nonobese diabetic mouse.
@en
P2093
P2860
P356
P1476
Differential effects of anti-B ...... n the nonobese diabetic mouse.
@en
P2093
D J Lenschow
J A Bluestone
K C Herold
P2860
P304
P356
10.1084/JEM.181.3.1145
P407
P577
1995-03-01T00:00:00Z